EFTA Document EFTA01447776

Editas has become the first of the group not only to attract crossover backers, but to begin discussing the diseases that its targeting. Its first program, Bosley says, is a potential treatment for a form of leber congenital amaurosis (LCA), a genetically driven blindness. It's a different form of the LCA than the gene therapy company Spark Therapeutics (NASDAQ: ONCE) is targeting; Bosley says the one Editas is going after can't be solved by gene therapy. Beyond that, and Editas's ongoing i